ProQR Therapeutics (NASDAQ:PRQR) was downgraded by equities research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a report released on Wednesday, ValuEngine reports.
A number of other equities analysts have also recently weighed in on PRQR. BidaskClub cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 20th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of ProQR Therapeutics in a report on Thursday, February 28th. Chardan Capital reiterated a “buy” rating and set a $25.00 price target (up from $21.00) on shares of ProQR Therapeutics in a report on Tuesday, March 12th. Finally, Zacks Investment Research cut ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $28.67.
NASDAQ PRQR opened at $11.66 on Wednesday. The firm has a market cap of $441.95 million, a PE ratio of -9.04 and a beta of 0.37. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.08 and a quick ratio of 10.08. ProQR Therapeutics has a twelve month low of $6.25 and a twelve month high of $24.00.
A number of institutional investors have recently made changes to their positions in PRQR. Morgan Stanley boosted its holdings in ProQR Therapeutics by 39.8% during the 3rd quarter. Morgan Stanley now owns 406,284 shares of the biopharmaceutical company’s stock valued at $7,862,000 after acquiring an additional 115,709 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ProQR Therapeutics during the 4th quarter valued at about $53,000. Virtus ETF Advisers LLC purchased a new position in ProQR Therapeutics during the 4th quarter valued at about $263,000. Lindbrook Capital LLC purchased a new position in ProQR Therapeutics during the 4th quarter valued at about $25,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in ProQR Therapeutics during the 4th quarter valued at about $124,000. Institutional investors own 61.75% of the company’s stock.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
See Also: How to Use the New Google Finance Tool
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.